107 related articles for article (PubMed ID: 23275992)
1. Effective hypolipidaemic therapy with beclobrate in haemodialysis patients: interference with L-carnitine.
Wanner C; Wieland H; Nauck M; Schaeffer G; Schollmeyer P; Hörl WH
Nephrol Dial Transplant; 1990; 5(8):588-93. PubMed ID: 23275992
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of beclobrate on lipid/lipoprotein distribution in normal and hypercholesterolemic rats.
Manzoni C; Lovati MR; Bonelli A; Galli G; Sirtori CR
Eur J Pharmacol; 1990 Nov; 190(1-2):39-49. PubMed ID: 2076759
[TBL] [Abstract][Full Text] [Related]
3. Beclobrate:pharmacodynamic properties and therapeutic use in hyperlipidemia.
Wanner C; Wieland H; Schollmeyer P; Hörl WH
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S85-9. PubMed ID: 2044651
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of beclobric acid enantiomers and their conjugates after single and multiple oral dosage of racemic beclobrate.
Mayer S; Spahn-Langguth H; Gikalov I; Mutschler E
Arzneimittelforschung; 1993 Jan; 43(1):40-3. PubMed ID: 8447845
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological studies with beclobrate, a new hypolipidemic agent.
Adrian RW; Ismail S; Jahn U
Arzneimittelforschung; 1983; 33(10):1464-8. PubMed ID: 6686044
[TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia.
Maebashi M; Kawamura N; Sato M; Imamura A; Yoshinaga K
Lancet; 1978 Oct; 2(8094):805-7. PubMed ID: 81361
[TBL] [Abstract][Full Text] [Related]
7. Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia type II a and type II b.
Najemnik C; Lageder H; Regal H; Irsigler K
Arzneimittelforschung; 1981; 31(12):2168-9. PubMed ID: 7037012
[TBL] [Abstract][Full Text] [Related]
8. Carnitine improves lipid anomalies in haemodialysis patients.
Lacour B; Di Giulio S; Chanard J; Ciancioni C; Haguet M; Lebkiri B; Basile C; Drüeke T; Assan R; Funck-Brentano JL
Lancet; 1980 Oct; 2(8198):763-4. PubMed ID: 6107451
[TBL] [Abstract][Full Text] [Related]
9. Influence of L-carnitine supplementation on serum lipid profile in hemodialysis patients: a systematic review and meta-analysis.
Huang H; Song L; Zhang H; Zhang H; Zhang J; Zhao W
Kidney Blood Press Res; 2013; 38(1):31-41. PubMed ID: 24525835
[TBL] [Abstract][Full Text] [Related]
10. [Beclobrate (Turec) in the treatment of primary hyperlipoproteinemia. I. Effect on cholesterol, lipid and apoprotein levels].
Sznajd J; Idzior-Waluś B; Zabiński J; Wybrańska I; Korzus G; Iwanejko J
Przegl Lek; 1990; 47(10):706-10. PubMed ID: 2089449
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics and bioequivalence of two peroral beclobrate preparations].
Gikalov I; Ifflaender U
Arzneimittelforschung; 1987 Sep; 37(9):1065-8. PubMed ID: 3435603
[TBL] [Abstract][Full Text] [Related]
12. A cross-over controlled study on beclobrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia.
Avogaro P; Bittolo Bon G; Cazzolato G; Soldan S; Bufalino L
Drugs Exp Clin Res; 1989; 15(6-7):325-33. PubMed ID: 2686956
[TBL] [Abstract][Full Text] [Related]
13. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients.
Naini AE; Sadeghi M; Mortazavi M; Moghadasi M; Harandi AA
Saudi J Kidney Dis Transpl; 2012 May; 23(3):484-8. PubMed ID: 22569432
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers.
Mayer S; Mutschler E; Benet LZ; Sphahn-Langguth H
Chirality; 1993; 5(3):120-5. PubMed ID: 8338721
[TBL] [Abstract][Full Text] [Related]
15. Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients.
Elisaf M; Bairaktari E; Katopodis K; Pappas M; Sferopoulos G; Tzallas C; Tsolas O; Siamopoulos KC
Am J Nephrol; 1998; 18(5):416-21. PubMed ID: 9730566
[TBL] [Abstract][Full Text] [Related]
16. Ketogenic and antiketogenic effects of L-carnitine in hemodialysis patients.
Wanner C; Wieland H; Wäckerle B; Boeckle H; Schollmeyer P; Hörl WH
Kidney Int Suppl; 1989 Nov; 27():S264-8. PubMed ID: 2636668
[TBL] [Abstract][Full Text] [Related]
17. Hyperlipoproteinemia in chronic renal failure: pathophysiological and therapeutic aspects.
Wanner C; Frommherz K; Hörl WH
Cardiology; 1991; 78(3):202-17. PubMed ID: 1868498
[TBL] [Abstract][Full Text] [Related]
18. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia.
Nikkilä EA; Ylikahri R; Huttunen JK
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608
[TBL] [Abstract][Full Text] [Related]
19. Effect of L-carnitine on lipid pattern in haemodialysis.
Casciani CU; Caruso U; Cravotto E; Corsi M; Pola P; Savi L; Grilli M
Lancet; 1980 Dec; 2(8207):1309-10. PubMed ID: 6108486
[No Abstract] [Full Text] [Related]
20. Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol.
Vacha GM; Giorcelli G; Siliprandi N; Corsi M
Am J Clin Nutr; 1983 Oct; 38(4):532-40. PubMed ID: 6624695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
